Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | RNF4 | P78317 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6733763 | 0.86 | MAPK14 (0.51) | MAPK14MMP2MMP9ALDH1A1TRPM8 | |
| SCHEMBL6736436 | 0.84 | MAPK14 (0.49) | MAPK14MMP2MMP9ALDH1A1TRPM8 | |
| SCHEMBL6738576 | 0.84 | MAPK14 (0.52) | MAPK14MMP2MMP9ALDH1A1TRPM8 | |
| SCHEMBL7420781 | 0.84 | CYP3A4 (0.44) | MAPK14ALDH1A1SMN1; SMN2TSHRNPSR1 | |
| SCHEMBL6739479 | 0.81 | NPY5R (0.51) | MLYCDMAPK14MMP2MMP9ALDH1A1 | |
| SCHEMBL6732824 | 0.80 | HTT (0.48) | MAPK14ALDH1A1TRPM8PDK1KDM4E | |
| SCHEMBL6738604 | 0.79 | GRM2 (0.58) | ALDH1A1RNF4LTB4R2TSHRGAA | |
| SCHEMBL4301089 | 0.78 | MLYCD (0.46) | MLYCDCYP1A2ALDH1A1PDK1SMN1; SMN2 | |
| SCHEMBL6730907 | 0.74 | MAPK14 (0.42) | MAPK14ALDH1A1TRPM8RNF4SMN1; SMN2 | |
| SCHEMBL16899931 | 0.74 | CYP1A2 (0.54) | MLYCDCYP1A2ALDH1A1TRPM8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | claimed |
| EP-1255735-A2 | PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-11-13 | — | — | EP | claimed |
| WO-2001056990-A2 | PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2001-08-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | GRM1, GRIN1, GRM2 | MLYCD 1787/4885MAPK14 3282/4885MMP2 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.